Michael Goettler - Pfizer Group President - Pfizer Upjohn

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Trending

  President
Mr. Michael Goettler Executive Vice President is Group President, Pfizer Upjohn since January 2019. He was Executive Vice President from July 2018 until December 2018. Global President of Pfizer Inflammation Immunology from January 2018 until June 2018. Global President of Pfizer Rare Disease from January 2016 until December 2017. Global Commercial Officer, Senior Vice President for Pfizers Global Innovative Pharma Business from January 2014 until December 2015. Regional President, Europe for Pfizer Specialty Care and the chair of the European Management Team from June 2012 until December 2013. Regional President Asia Pacific for Specialty Care from October 2009 until June 2012. Member of the board of directors of PSI .
Age: 50  President Since 2019      
212 733-2323  www.pfizer.com

Michael Goettler Latest Insider Activity

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 0.0828 % which means that on every $100 spent on asset it made $0.0828 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 20.94 % implying that it generated $20.94 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 0.0008. Pfizer Tax Assets are expected to significantly decrease based on the last few years of reporting. The last year's Tax Assets were at 5.44 Billion. The current year Revenue to Assets is expected to grow to 0.35, whereas Assets Non Current are expected to decline to about 124.2 B. Pfizer Tax Liabilities is expected to significantly decrease based on the last few years of reporting. The last year's Tax Liabilities was at 18.68 Billion
The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer Inc has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

PRESIDENT Since

Sripada ChandrasekharDr Reddys Laboratories
2013
Louis YuPerrigo Company Plc
2013
Jay MarkowitzRegeneron Pharmaceuticals
2017
Ganadhish KamatDr Reddys Laboratories
2016
Jatin ShahPerrigo Company Plc
2005
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Michael AbermanRegeneron Pharmaceuticals
2015
James DillardPerrigo Company Plc
2019
Michael PariniVertex Pharmaceuticals Incorpor
2017
J RamachandranDr Reddys Laboratories
2016
George YancopoulosRegeneron Pharmaceuticals
2016
Glenn DavidZoetis Inc
2016
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Marion McCourtRegeneron Pharmaceuticals
2018
Heidi ChenZoetis Inc
2012
Thomas FarringtonPerrigo Company Plc
2015
Samiran DasDr Reddys Laboratories
2016
Roman TrawickiZoetis Inc
2015
Amit SachdevVertex Pharmaceuticals Incorpor
2017
Scott JamisonPerrigo Company Plc
2011
Thomas GraneyVertex Pharmaceuticals Incorpor
2017

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer Inc (PFE) is traded on BATS Exchange in USA and employs 88,300 people.

Pfizer Inc Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Dennis Ausiello, Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Director
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President, Pfizer Biopharmaceuticals Group
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Stock Performance Indicators

Current Sentiment - PFE

Pfizer Inc Investor Sentiment

Predominant part of Macroaxis users are at this time bullish on Pfizer Inc. What is your perspective on investing in Pfizer Inc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

GOOG   
Purchased few shares of
few hours ago
Traded for 1412.1801
MSFT   
Purchased few shares of
few hours ago
Traded for 182.92
CRM   
Purchased few shares of
few hours ago
Traded for 171.44
DD   
Purchased over 50 shares of
few hours ago
Traded for 54.98
FB   
Purchased few shares of
few hours ago
Traded for 226.29
Please check Your Equity Center. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page